Inflammation, a key event in cancer development

Molecular Cancer Research

Volumn 4, Issue 4, 2006, Pages 221-233

  Lu, Haitian ^a   Ouyang, Weiming ^a   Huang, Chuanshu ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; STAT PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RESEARCH; CARCINOGENESIS; CELL TRANSFORMATION; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; METASTASIS; MICROENVIRONMENT; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; HUMANS; INFLAMMATION; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 33646160623     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-05-0261     Document Type: Review

References (221)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
2. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-9.
3. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
4. Okada F. Inflammation and free radicals in tumor development and progression. Redox Rep 2002;7:357-68.
5. Yang CR, Hsieh SL, Ho FM, Lin WW. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-κB-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 2005;174:1647-56.
6. Nathan C. Points of control in inflammation. Nature 2002;420:846-52.
7. Maiuri MC, Tajana G, Iuvone T, et al. Nuclear factor-κB regulates inflammatory cell apoptosis and phagocytosis in rat carrageenin-sponge implant model. Am J Pathol 2004;165:115-26.
8. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001;2:612-9.
9. Hodge-Dufour J, Marino MW, Horton MR, et al. Inhibition of interferon γ induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci U S A 1998;95:13806-11.
10. Savill J, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989;83:865-75.
11. Savill J, Fadok VA. Corpse clearance defines the meaning of cell death. Nature 2000;407:784-8.
12. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002;2:965-75.
13. 2 and PAF. J Clin Invest 1998;101:890-8.
14. McDonald PP, Fadok VA, Bratton D, Henson PM. Transcriptional and translational regulation of inflammatory mediator production by endogenous TGF-β in macrophages that have ingested apoptotic cells. J Immunol 1999;163:6164-72.
15. Huynh M-LN, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β secretion and the resolution of inflammation. J Clin Invest 2002;109:41-50.
16. Macarthur M, Hold GL, El-Omar EM. Inflammation and cancer. II. Role of chronic inflammation and cytokine polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 2004;286:G515-20.
17. Berenblum I. The cocarcinogenic action of croton resin. Cancer Res 1941;1:44-8.
18. Trosko JE. Commentary: is the concept of "tumor promotion" a useful paradigm? Mol Carcinog 2001;30:131-7.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
20. Schreiber H, Rowley DA. Inflammation and cancer. In: Gallin JI, Snyderman R, editors. Inflammation: basic principles and clinical correlates. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 1117-29.
21. Itzkowitz SH, Yio X. Inflammation and cancer. IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
22. Seril DN, Lia J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003;24:353-62.
23. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis; a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-83.
24. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol Ther 2000;14:145-53.
25. Keeley D, Rees J. New guidelines in asthma management. Br Med J 1997;314:315-6.
26. Borm PJ, Driscoll K. Particles, inflammation and respiratory tract carcinogenesis. Toxicol Lett 1996;88:109-13.
27. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-107.
28. Rosin MR, Anwar WA, Ward AJ. Inflammation, chromosomal instability, and cancer: the schistosomiasis model. Cancer Res 1994;54:1929-33S.
29. Whitcomb DC. Inflammation and cancer. V. chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004;287:G315-9.
30. Vesterinen E, Pukkala E, Timonen T, Aromaa A. Cancer incidence among 78,000 asthma patients. Int J Epidemiol 1993;22:976-82.
31. Alavanja MC, Brownson RC, Boice JD, Hock E. Preexisting lung disease and lung cancer among nonsmoking women. Am J Epidemiol 1992;136:623-32.
32. Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995;141:1023-32.
33. Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A. Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 1999;160:1668-72.
34. Carlson JA, Ambros R, Malfetano J, et al. Vulvar lichen sclerosus and squamous cell carcinoma: a cohort, case control, and investigational study with historical perspective; implications for chronic inflammation and sclerosis in the development of neoplasia. Hum Pathol 1998;29:932-48.
35. Mayron R, Grimwood RE, Siegle RJ, Camisa C. Verrucous carcinoma arising in ulcerative lichen planus of the soles. J Dermatol Surg Oncol 1988;14:547-51.
36. Perky L. Epidemiology of cancer of the penis. Recent Results Cancer Res 1977;60:97-109.
37. Risch HA, Howe GR. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 1995;4:447-51.
38. Palapattu GS, Sutcliffe S, Bastian PJ, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2004;26:1170-81.
39. Cordon-Cardo C, Prives C. Commentary: at the crossroads of inflammation and tumorigenesis. J Exp Med 1999;190:1367-70.
40. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone-marrow-derived cells. Science 2004;306:1568-71.
41. Maeda H, Akaike H. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-65.
42. Fulton AM, Loveless SE, Heppner GH. Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA100. Cancer Res 1984;44:4308-11.
43. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-8.
44. Hudson JD, Shoaibi MA, Maestro R, Carnero A, Hannon GJ, Beach DH. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med 1999;190:1375-82.
45. Petrenko O, Moll UM. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 2005;17:225-36.
46. Chu FF, Esworthy RS, Chu PG, et al. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 2004;64:962-8.
47. Lin EY, Pollard JW. Role of infiltrated leucocytes in tumor growth and spread. Br J Cancer 2004;90:2053-8.
48. Coussens LM, Werb Z. Inflammatory cells and cancer: think different! J Exp Med 2001;193:F23-6.
49. Clark WH, Jr., Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
50. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77:1303-10.
51. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998;58:3491-4.
52. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
53. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med 2003;348:203-13.
54. Dunn G, Bruce A, Ikeda H, Old L, Schreiber R. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
55. Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis 2002;19:247-58.
56. Tsung K, Dolan JP, Tsung YL, Norton JA. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res 2002;62:5069-75.
57. Mihm M, Clemente C, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases - a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-7.
58. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93.
59. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
60. Saji H, Koike M, Yamori T, et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 2001;92:3282-9.
61. Leek RD, Harris AL. Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 2002;7:177-89.
62. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor, CSF-1, in mammary gland development and cancer. J Mammary Gland Biol Neoplasia 2002;7:147-62.
63. Kacinski BM. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol Reprod Dev 1997;46:71-4.
64. Amann B, Perabo FG, Wirger A, Hugenschmidt H, Schultze-Seemann W. Urinary levels of monocyte chemo-attractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br J Urol 1998;82:118-21.
65. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N. Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 1998;194:335-40.
66. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 1990;66:2012-6.
67. Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J Urol 1998;160:214-9.
68. Lespagnard L, Gancberg D, Rouas G, et al. Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer 1999;84:309-14.
69. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol 2001;115:514-21.
70. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999;189:487-95.
71. Bellocq A, Antoine M, Flahault A, et al. Neutrophil alveolitis in bronchioloalveolar carcinoma: induction by tumor-derived interleukin-8 and relation to clinical outcome. Am J Pathol 1998;152:83-92.
72. Caruso RA, Bellocco R, Pagano M, Bertoli G, Rigoli L, Inferrera C. Prognostic value of intratumoral neutrophils in advanced gastric carcinoma in a high-risk area in northern Italy. Mod Pathol 2002;15:831-7.
73. Elgert K, Alleva D, Mullins D. Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 1998;64:275-90.
74. Grimshaw MJ, Wilson JL, Balkwill FR. Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors. Eur J Immunol 2002;32:2393-400.
75. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
76. Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 1998;110:27-32.
77. Fox SB, Taylor M, Grondahl-Hansen J, Kakolyris S, Gatter KC, Harris AL. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. J Pathol 2001;195:236-43.
78. Knoop A, Andreasen PA, Andersen JA, et al. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br J Cancer 1998;77:932-40.
79. Hildenbrand R, Wolf G, Bohme B, Bleyl U, Steinborn A. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol 1999;66:40-9.
80. Bando H, Toi M. Tumor angiogenesis, macrophages, and cytokines. Adv Exp Med Biol 2000;476:267-84.
81. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA, Harris AL. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 2000;190:430-6.
82. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43.
83. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17:2115-7.
84. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999;13:1382-97.
85. Ogmundsdottir HM, Petursodottir I, Gudmundsdottir I. Interactions between the immune system and breast cancer. Acta Oncol 1995;34:647-50.
86. O'Sullivan C, Lewis CE, Harris AL, McGee JO. Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet 1993;342:872-3.
87. Wyckoff JB, Segall JE, Condeelis JS. The collection of the motile population of cells from a living tumor. Cancer Res 2000;60:5401-4.
88. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004;64:7022-9.
89. Fijneman RJ, Vos M, Berkhof J, Demant P, Kraal G. Genetic analysis of macrophage characteristics as a tool to identify tumor susceptibility genes: mapping of three macrophage-associated risk inflammatory factors, Marif1, Marif2, and Marif3. Cancer Res 2004;64:3458-64.
90. Meininger CJ, Zetter BR. Mast cells and angiogenesis. Semin Cancer Biol 1992;3:73-9.
91. Qu Z, Liebler JM, Powers MR, et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995;147:564-73.
92. Hiromatsu Y, Toda S. Mast cells and angiogenesis. Microsc Res Tech 2003;60:64-9.
93. Scapini P, Nesi L, Morini M, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002;168:5798-804.
94. Schaider H, Oka M, Bogenrieder T, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003;103:335-43.
95. Haqqani AS, Sandhu JK, Birnboim HC. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors. Neoplasia 2000;2:561-8.
96. + T cells. J Exp Med 2003;197:1017-28.
97. Bromwich EJ, McArdle PA, Canna K, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003;89:1906-8.
98. Canna K, McArdle PA, McMillan DC, et al. The relationship between tumour T-lymphocyte infiltration, the systematic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005;92:651-4.
99. Becker C, Fantini MC, Schramm C, et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501.
100. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
101. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 2003;83:222-6.
102. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates colonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 2000;151:31-8.
103. Tebbutt NC, Giraud AS, Inglese M, et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002;8:1089-97.
104. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002;13:135-41.
105. Huang C, Li J, Ma WY, Dong Z. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-α but not by 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 1999;274:29672-6.
106. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90.
107. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104:487-501.
108. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-90.
109. Wu S, Boyer CM, Whitaker RS, et al. Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor α expression. Cancer Res 1993;53:1939-44.
110. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE. Association of tumour necrosis factor α and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 1998;77:2246-51.
111. Aggarwal BB. Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-56.
112. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002;12:113-20.
113. Ardestani SK, Inserra P, Solkoff D, Watson RR. The role of cytokines and chemokines on tumor progression: a review. Cancer Detect Prev 1999;23:215-25.
114. Strieter RM. Chemokines: not just leukocyte chemoattractants in the promotion of cancer. Nat Immunol 2001;2:285-6.
115. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997;151:1105-13.
116. Inoue K, Slaton JW, Eve BY, et al. Interleukin-8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res 2000;6:2104-19.
117. Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6.
118. Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors. Cancer Res 2001;61:4961-5.
119. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-58.
120. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621-63.
121. Viatour P, Merville M-P, Bours V, Chariot A. Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005;30:43-52.
122. Kato T, Jr., Delhase M, Hoffmann A, Karin M. CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response. Mol Cell 2003;12:829-39.
123. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. IκB kinase-independent IκBα degradation pathway: functional NF-κB activity and implications for cancer therapy. Mol Cell Biol 2003;23:8070-83.
124. Baldwin A. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
125. Sweeney C, Li L, Shanmugam R, et al. Nuclear factor-κB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 2004;10:5501-7.
126. Hu J, Haseebuddin M, Young M, Colburn NH. Suppression of p65 phosphorylation coincides with inhibition of IκBα polyubiquitination and degradation. Mol Carcinog 2005;44:274-84.
127. Hu J, Nakano H, Sakurai H, Colburn NH. Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NFκB activation and transformation in resistant JB6 cells. Carcinogenesis 2004;25:1991-2003.
128. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
129. Caamano J, Hunter C. NF-κB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002;15:414-29.
130. Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol 2002;2:725-34.
131. Senftleben U, Li ZW, Baud V, Karin M. IKKβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity 2001;14:217-30.
132. Mora A, Youn J, Keegan A, Boothby MR. NF-κB/Rel participation in the lymphokine-dependent proliferation of T lymphoid cells. J Immunol 2001;166:2218-27.
133. Hettmann T, DiDonato J, Karin M, Leiden JM. An essential role for nuclear factor-κB in promoting double-positive thymocyte apoptosis. J Exp Med 1999;189:145-58.
134. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
135. Perkins ND. The Rel/NF-κB family: friend and foe. Trends Biochem Sci 2000;25:434-40.
136. Heyninck K, Beyaert R. A20 inhibits NF-κB activation by dual ubiquitin-editing functions. Trends Biochem Sci 2005;30:1-4.
137. Pasparakis M, Courtois G, Hafner M, et al. TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 2002;417:861-6.
138. Chen LW, Egan L, Li ZW, Greten FR, Kagnoff MF, Karin M. The two faces of IKK and NF-êB inhibition: prevention of systematic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med 2003;9:575-81.
139. Hollenbach E, Vieth M, Roessner A, Neumann M, Malfertheiner P, Naumann M. Inhibition of RICK/nuclear factor-κB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem 2005;280:14981-8.
140. Bakkouri KE, Wullaert A, Haegman M, Heyninck K, Beyaert R. Adenoviral gene transfer of the NF-κB inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model. J Biol Chem 2005;280:17938-44.
141. Cataisson C, Pearson AJ, Torgerson S, Nedospasov SA, Yuspa SH. Protein kinase Cα-mediated chemotaxis of neutrophils requires NF-κB activity but is independent of TNFα signaling in mouse skin in vivo. J Immunol 2005;174:1686-92.
142. Francois S, Benna JE, Dang PMC, Pedruzzi E, Gougerot-Pocidalo M-A, Elbim C. Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-κB signaling pathways, leading to increased levels of MCl-1, Al, and phosphorylated bad. J Immunol 2005;174:3633-42.
143. Lin A, Karin M. NF-κB in cancer: a marked target. Semin Cancer Biol 2003;13:107-14.
144. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
145. 2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins. Blood 2005;105:1750-8.
146. Stoffel A, Chaurushiya M, Singh B, Levine AJ. Activation of NF-κB and inhibition of p53-mediated apoptosis by AP12/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci U S A 2004;101:9079-84.
147. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS, Jr. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19:5785-99.
148. 1-to-S-phase transition. Mol Cell Biol 1999;19:2690-8.
149. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569-81.
150. Preciado D, Caicedo E, Jhanjee R, et al. Pseudomonas aeruginosa lipopolysaccharide induction of keratinocyte proliferation, NF-κB, and cyclin D1 is inhibited by indomethacin. J Immunol 2005;174:2964-73.
151. Chen CC, Rosenbloom CL, Anderson DC, Manning AM. Selective inhibition of E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 expression by inhibitors of IκBα phosphorylation. J Immunol 1995;155:3538-45.
152. Furbert-Harris PM, Parish-Gause D, Hunter KA, et al. Activated eosinophils upregulate the metastasis suppressor molecule E-cadherin on prostate tumor cells. Cell Mol Biol 2003;49:1009-16.
153. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Clinical significance of serum levels of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients. Am J Gastroenterol 2003;98:478-85.
154. Esposito V, Groeger AM, De Luca L, et al. Expression of surface protein receptors in lung cancer. Anticancer Res 2002;22:4039-43.
155. O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C, Given HF. Soluble adhesion molecules (E-selectin, ICAM-1, and VCAM-1) in breast carcinoma. Eur J Cancer 2002;38:2252-7.
156. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1α in induction of constitutive NF-κB activation in pancreatic cancer cells. J Biol Chem 2004;279:16452-62.
157. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature 2004;431:461-6.
158. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118: 285-96.
159. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109:S81-96.
160. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305.
161. Kim YH, Woo KJ, Lim JH, et al. 8-Hydroxyquinoline inhibits iNOS expression and nitric oxide production by down-regulating LPS-induced activity of NF-κB and C/EBPβ in Raw 264.7 cells. Biochem Biophys Res Commun 2005;329:591-7.
162. Chen T, Nines RG, Peschke SM, Kresty LA, Stoner GD. Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis. Cancer Res 2004;64:3714-7.
163. Hussain SP, Trivers GE, Hofseth LJ, et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 2004;64:6849-53.
164. Hofseth LJ, Hussain SP, Wogan GN, Harris CC. Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 2003;34:955-68.
165. Colón AL, Menchén LA, Hurtado O, et al. Implication of TNF-α convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine 2001;16:220-6.
166. Goodman JE, Hofseth LJ, Hussain SP, Harris CC. Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen 2004;44:3-9.
167. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004;555:107-19.
168. Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2003;100:143-8.
169. Tatemichi M, Sawa T, Gilibert I, Tazawa H, Katoh T, Ohshima H. Increased risk of internal type of gastric adenocarcinoma in Japanese women associated with long forms of CCTTT pentanucleotide repeat in the inducible nitric oxide synthase promoter. Cancer Lett 2005;217:197-202.
170. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
171. Steele VE, Hawk ET, Viner JL, Lubert RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 2003;523-524:137-44.
172. Buskens CJ, Van Rees BP, Sivula A, et al. Prognostic significance of elevated cyclooxygenase-2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002;122:1800-7.
173. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
174. Giardiello FM, Offerhaus GJ, DuBois RN. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 1995;31A:1071-6.
175. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
176. Prescott SM, Fitzpatrick FA. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 2000;1470:M69-78.
177. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
178. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase 2 in human gastric cancer. Cancer Res 1997;57:1276-80.
179. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-60.
180. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-24.
181. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761-4.
182. 2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol 2004;287:L981-91.
183. Oyama K, Fujimura T, Ninomiya I, et al. A COX-2 inhibitor prevents esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 2004;26:565-70.
184. Abdalla SI, Sanderson IR, Fitzgerald RC. Effect of inflammation on cyclooxygenase-2 expression in benign and malignant oesophageal cells. Carcinogenesis 2005;26:1627-33.
185. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005;11:3250-6.
186. Klein RD, Van Pelt CS, Sabichi AL, et al. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res 2005;65:1808-13.
187. 4 signaling, inflammation, and cancer. J Natl Cancer Inst 2003;95:1028-9.
188. 2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
189. Salceda S, Caro J. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642-7.
190. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999;15:551-78.
191. 2 integrin gene expression. Proc Natl Acad Sci U S A 2004;101:10440-5.
192. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004;114:1098-106.
193. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003;112:645-57.
194. Walmsley SR, Print C, Farahi N, et al. Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J Exp Med 2005;201:105-15.
195. Makino Y, Nakamura H, Ikeda E, et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol 2003;171:6534-40.
196. Zhou J, Schmid T, Brüne B. Tumor necrosis factor-α causes accumulation of a ubiquitinated form of hypoxia inducible factor-1α through a nuclear factor-κB-dependent pathway. Mol Biol Cell 2003;14:2216-25.
197. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L. Hypoxia-inducible factor induction by tumor necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor κB activation. Biochem J 2003;370:1011-7.
198. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29:3-9.
199. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41:2502-12.
200. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65:939-47.
201. Hodge DR, Xiao W, Wang LH, Li D, Farrar WL. Activating mutations in STAT3 and STAT5 differentially affect cellular proliferation and apoptotic resistance in multiple myeloma cells. Cancer Biol Ther 2004;3:483-9.
202. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10:48-54.
203. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004;10:549-57.
204. Cho HY, Reddy SPM, Yamamoto M, Kleeberger SR. The transcription factor NRF2 protects pulmonary fibrosis. FASEB J 2004;18:1258-60.
205. Rangasamy T, Cho CY, Thimmulappa RK, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004;114:1248-59.
206. Braun S, Hanselmann C, Gassmann MG, et al. Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 2002;22:5492-505.
207. 2. Mol Cell Biol 2004;24:36-45.
208. Buckley BJ, Marshall ZM, Whorton AR. Nitric oxide stimulates Nrf2 nuclear translocation in vascular endothelium. Biochem Biophys Res Commun 2003;307:973-9.
209. Morito N, Yoh K, Itoh K, et al. Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene 2003;22:9275-81.
210. Bae I, Fan S, Meng Q, et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004;64:7893-909.
211. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. J Biol Chem 2003;278:8135-45.
212. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15:707-47.
213. 2+, calcineurin and NFAT. Cell 1999;96:611-4.
214. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000;12:359-72.
215. + T cells. J Immunol 2003;170:3109-17.
216. Diehl S, Krahl T, Rinaldi L, Norton R, Irvin CG, Rincón M. Inhibition of NFAT specifically in T cells prevents allergic pulmonary inflammation. J Immunol 2004;172:3597-603.
217. Duque J, Fresno M, Iniguez MA. Expression and function of the nuclear factor of activated T cells in colon carcinoma cells. J Biol Chem 2005;289:8686-93.
218. Jimenez JL, Iniguez MA, Munoz-Fernández MA, Fresno M. Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell Signal 2004;16:1363-73.
219. Maderna P, Godson C. Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim Biophys Acta 2003;1639:141-51.
220. Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001;22:199-204.
221. Fitzpatrick FA. Inflammation, carcinogenesis and cancer. Int Immunopharmacol 2001;1:1651-67.